# Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis

> **NIH NIH U01** · JOHNS HOPKINS UNIVERSITY · 2020 · $1,297,756

## Abstract

Multiple sclerosis (MS) is an immune-mediated, inflammatory disorder of the central nervous system. Despite
being classically considered a demyelinating disorder, it has been demonstrated that neuro-axonal injury occurs
early in the disease course and represents the pathologic substrate for permanent neurological disability in
people with MS (PwMS). In clinical practice, disease monitoring in PwMS is performed by clinical evaluation and
use of conventional magnetic resonance imaging (MRI) measures, including new T2 lesions and/or presence of
T1 post-gadolinium (Gd) enhancing lesions. Notably, these conventional MRI measures assess for the presence
of inflammatory disease activity rather than neuro-axonal loss and are only modestly associated with clinical
measures of disability in MS, a phenomenon known as the “clinico-radiological paradox”. There is an unmet
need in MS for a biomarker that may identify PwMS with ongoing neuro-axonal damage prior to the
accrual of permanent clinical disability, in order to allow for timely intervention.
 Neurofilaments are neuron-specific cytoskeletal proteins that are released following neuro-axonal
damage. Increased neurofilament light chain (NfL) levels have been found in the blood and cerebrospinal fluid
(CSF) in several neurological disorders, including MS. In MS, there is evidence that serum NfL (sNfL) levels
correlate closely with CSF NfL levels, are associated with clinico-radiological measures of disease activity, are
modulated by disease modifying therapies (DMTs), and predict disability worsening and brain atrophy. However
these data are derived mainly from small, single-center studies, and the influence of factors including
demographics, disease subtype, and co-morbid conditions on sNfL levels in MS remains poorly characterized.
It is also remains unclear if sNfL levels may be used to monitor response to therapy, guide decision-making
regarding potency of immunotherapy, and predict long-term outcomes. While, given this emerging evidence,
there is great interest in sNfL for use as a prognostic and monitoring biomarker of neuro-axonal injury
in MS, further clinical validation is necessary in larger, demographically diverse, clinically
heterogeneous, multi-center cohorts. Furthermore, it is of utmost importance that validation is
performed utilizing a robust, scalable assay that may be rapidly implemented in the clinical realm.
 We plan to measure sNfL utilizing a novel automated immunoassay (Siemens Healthineers; performed
on an existing clinically available platform) in serum samples from two large multi-center studies: 1) MS PATHS
(Multiple Sclerosis Partners Advancing Technology and Health Solutions) is a network of 10 healthcare
institutions in the United States and Europe, merging research with ongoing patient care by collecting
standardized clinical/imaging data and biospecimens during routine medical visits. As of February 1st, 2019,
>15,000 patients have opted to participate in MS PATHS with bio...

## Key facts

- **NIH application ID:** 9873392
- **Project number:** 1U01NS111678-01A1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** PETER A CALABRESI
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,297,756
- **Award type:** 1
- **Project period:** 2020-01-01 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9873392

## Citation

> US National Institutes of Health, RePORTER application 9873392, Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis (1U01NS111678-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9873392. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*